A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and ...

NEW ALBANY — Baptist Health Floyd recently completed its 500th Watchman procedure. The Watchman device is an alternative to ...

The study evaluated the company’s Watchman FLX device, designed to reduce stroke risk in patients with non valvular atrial ...

Study suggests a path forward for device therapy, though caveats are plenty ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.

Today, March 30, 2026, investors send Boston Scientific shares lower as they dig deeper into the company's latest trial ...

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...